Clinical Trials /

Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma

NCT04655157

Description:

Patients with unresectable or metastatic BRAF-mutant melanoma high-risk patients will be given 450 mg orally (PO) daily (QD) plus binimetinib 45 mg PO twice daily (BID) together with nivolumab administered intravenously (IV) at 3mg/kg and ipilimumab administered IV at 1 mg/kg every 3 weeks for 4 doses, followed by nivolumab administered IV at 480mg every 4 weeks until progression or discontinuation due to toxicity. Concurrently, a triple therapy arm will be explored with encorafenib 300 mg PO QD together with ipilimumab administered IV at 1mg/kg and nivolumab 3mg/kg IV every 3 weeks for 4 doses, followed by nivolumab administered at 480mg every 4 weeks until progression or discontinuation due to toxicity. Tolerability of the two arms will be compared, and a recommended phase 2 dose (RP2D) will be determined. After determination of treatment schedule, expansion cohorts will further explore the preliminary efficacy and further describe the toxicity profile of the triplet or quadruplet regimen in high-risk cohorts including symptomatic brain metastases or liver metastases with elevated lactate dehydrogenase (LDH) or bulky systemic disease burden.

Related Conditions:
  • Melanoma
Recruiting Status:

Not yet recruiting

Phase:

Phase 1/Phase 2

Trial Eligibility

Document

Title

  • Brief Title: Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma
  • Official Title: A Multi-Center Phase I/II Open Label Study to Evaluate Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimumab. (QUAD 01: Quadruple Therapy in Melanoma)

Clinical Trial IDs

  • ORG STUDY ID: HCC 20-190
  • SECONDARY ID: CA209-7Y4
  • NCT ID: NCT04655157

Conditions

  • Melanoma

Interventions

DrugSynonymsArms
encorafenibBRAFTOVI®Phase 1 (cohort 1): 300mg encorafenib + 3mg/kg nivolumab + 1 mg/kg ipilimumab
nivolumabOPDIVO®Phase 1 (cohort 1): 300mg encorafenib + 3mg/kg nivolumab + 1 mg/kg ipilimumab
ipilimumabYervoy®Phase 1 (cohort 1): 300mg encorafenib + 3mg/kg nivolumab + 1 mg/kg ipilimumab
binimetinibMektovi, ARRY-162Phase 1 (cohort 2): 450mg encorafenib + 45mg binimetinib + 3mg/kg nivolumab + 1mg/kg ipilimumab

Purpose

Patients with unresectable or metastatic BRAF-mutant melanoma high-risk patients will be given 450 mg orally (PO) daily (QD) plus binimetinib 45 mg PO twice daily (BID) together with nivolumab administered intravenously (IV) at 3mg/kg and ipilimumab administered IV at 1 mg/kg every 3 weeks for 4 doses, followed by nivolumab administered IV at 480mg every 4 weeks until progression or discontinuation due to toxicity. Concurrently, a triple therapy arm will be explored with encorafenib 300 mg PO QD together with ipilimumab administered IV at 1mg/kg and nivolumab 3mg/kg IV every 3 weeks for 4 doses, followed by nivolumab administered at 480mg every 4 weeks until progression or discontinuation due to toxicity. Tolerability of the two arms will be compared, and a recommended phase 2 dose (RP2D) will be determined. After determination of treatment schedule, expansion cohorts will further explore the preliminary efficacy and further describe the toxicity profile of the triplet or quadruplet regimen in high-risk cohorts including symptomatic brain metastases or liver metastases with elevated lactate dehydrogenase (LDH) or bulky systemic disease burden.

Detailed Description

      Study participants will consist of metastatic melanoma patients harboring BRAFV600E/K
      mutation without previous frontline therapy (or > 6 months from adjuvant therapy). Toxicity
      from prior treatment must have resolved to ≤ Grade 1 and not included previous Grade 3-4
      immune-related adverse events (irAEs) that required treatment discontinuation or previous
      Grade 2 immune-related uveitis or pneumonitis.

      Phase I, Cohort 1: Twelve patients will be treated with 300mg encorafenib and 3mg/kg
      nivolumab and 1 mg/kg ipilimumab. The dose limiting toxicity (DLT) for cohort 1 will be
      evaluated between weeks 1-6.

      Phase I, Cohort 2: Upfront quadruple therapy with 450mg encorafenib, 45mg binimetinib, 3mg/kg
      nivolumab and 1mg/kg ipilimumab will be investigated with 12 participants. DLT window for
      phase I, cohort 2 will be evaluated at weeks 1-6.

      Upon establishment of RP2D schedule, only participants with advanced melanoma who are either
      treatment naïve in the metastatic setting or who have progressed on adjuvant therapy for more
      than 6 months following completion of adjuvant therapy (either BRAF-MEK or PD1 Ab) will be
      eligible for participation in high risk disease cohort expansion (Groups 1 or 2).

      Phase II will employ the RP2D schedule from Phase I and investigate the early efficacy in
      participants with high risk features who are less likely to derive benefit from standard
      treatment approaches and who may benefit from quadruple therapy despite the potential for
      increased toxicity. These will include: Group 1) symptomatic brain metastases [up to 30
      patients] and Group 2) Elevated LDH >1x upper limit of normal (ULN) with: a) liver metastases
      OR b) bulky visceral disease (sum of longest diameter (SLD) > 44mm) [combined with Group 1 up
      to 60 total patients].

      Following initiation of triple or quadruple therapy, participants will be followed for safety
      and response. Safety assessments will be a high priority with on-going Bayesian toxicity
      monitoring and efficacy assessments every 12 weeks. Based on prior targeted, immune, and
      triplet therapy studies, we anticipate up to 30-50% DLT and will consider temporary
      suspension of trial enrollment with a DLT > 75% as determined by CTCAEv5. Treatment efficacy
      will be documented using RECIST 1.1 and RANO-BM criteria, recorded every 4-12 weeks, and
      immune-RECIST (iRECIST) and immune-RANO (iRANO) criteria.
    

Trial Arms

NameTypeDescriptionInterventions
Phase 1 (cohort 1): 300mg encorafenib + 3mg/kg nivolumab + 1 mg/kg ipilimumabExperimentalPatients will be treated with 300mg encorafenib and 3mg/kg nivolumab and 1 mg/kg ipilimumab (triple therapy).
  • encorafenib
  • nivolumab
  • ipilimumab
Phase 1 (cohort 2): 450mg encorafenib + 45mg binimetinib + 3mg/kg nivolumab + 1mg/kg ipilimumabExperimentalPatients will be treated with 450mg encorafenib, 45mg binimetinib, 3mg/kg nivolumab and 1mg/kg ipilimumab (quadruple therapy).
  • encorafenib
  • nivolumab
  • ipilimumab
  • binimetinib

Eligibility Criteria

        Inclusion Criteria:

          1. Signed Written Informed Consent

               1. Participants must have signed and dated an IRB/IEC approved written informed
                  consent form in accordance with regulatory and institutional guidelines. This
                  must be obtained before the performance of any protocol-related procedures that
                  are not part of normal subject care.

               2. Participants must be willing and able to comply with scheduled visits, treatment
                  schedule, laboratory testing, and other requirements of the study.

          2. Age ≥18 years

          3. Histologically confirmed diagnosis of unresectable or metastatic melanoma

          4. Presence of BRAFV600E/K mutation in tumor tissue as determined in a CLIA certified
             laboratory

          5. Patients are required to submit archival biopsy material, if available, and submit
             research blood samples prior to first dose. Ten patients in each Phase Ib cohort will
             undergo fresh biopsy. These will be the first 10 unless medical or societal factors
             (e.g. COVID19) limit the pursuit of research biopsies.

          6. Patients must be greater than 6 months from completion of adjuvant therapy (if any
             given) and/or treatment naïve in the metastatic setting.

          7. Prior radiotherapy must have been completed at least 2 weeks prior to study drug
             administration.

          8. An ECOG Performance Status of 0 or 1. If enrolling in Group 1 of Phase II, can have
             Performance Status from 0-2.

          9. Measurable disease by CT or MRI per RANO-BM (brain metastases) OR RECIST v1.1 criteria

         10. Must have high risk features described as described in Phase II expansion cohort -
             EITHER brain metastases as described in Phase II Group 1 OR Elevated LDH/Bulky
             Visceral Disease as described in Phase II Group 2.

         11. Adequate bone marrow, organ function, and laboratory parameters:

               1. ANC > 1.5 x 109 ¬ /L;

               2. Hemoglobin > 8 g/dL with or without transfusions;

               3. Platelet > 100 x 109 ¬ /L;

               4. Serum creatinine ≤ 1.5 × ULN, OR calculated creatinine clearance > 50 mL/min by
                  Cockcroft-Gault formula, OR estimated glomerular filtration rate > 50 mL/min/1.73
                  m

         12. Patient IS permitted to be on corticosteroids if related to disease burden and MAY
             have symptomatic brain lesions as long as radiation or surgical intervention is not
             deemed to be urgently necessary.

               1. Symptomatic intracranial metastases may be on steroids at a total daily dose of
                  no higher than 4 mg of dexamethasone or equivalent that is stable or tapering for
                  10 days prior to first treatment,

               2. have no immediate need for SRT or surgery (within 3 week prior to first
                  treatment),

               3. have a performance status of 0-2 and

               4. have had no experience of seizure within 10 days prior to first treatment.

         13. Female patients of childbearing potential must have a negative serum β-HCG test result
             during screening prior to first dose

         14. Females of childbearing potential must agree to protocol-approved methods of
             contraception, and to not donate Ova from Screening until 30 days of last dose of
             study drug.

         15. Male patients must use contraception that is highly effective or acceptable, and not
             donate sperm from Screening until 90 days after the last dose of study drug.

         16. The patient is deemed by the Investigator to have the initiative and means to comply
             with scheduled visits, treatment plan and study procedures.

        Exclusion Criteria:

          1. Known hypersensitivity or contraindication to any component of study treatment or
             their excipients.

          2. Previous Grade 3-4 AEs, or discontinuation of PD-1 or CTLA-4 inhibitor therapy, or
             BRAF/MEK inhibitor therapy

          3. Inability to swallow and retain study treatment

          4. Impairment of gastrointestinal function or disease which may significantly alter the
             absorption of study treatment (e.g., active ulcerative disease; uncontrolled nausea,
             vomiting or diarrhea; malabsorption syndrome; small bowel resection).

          5. Participants with a non-melanoma related condition requiring systemic treatment with
             either corticosteroids (> 10 mg daily prednisone equivalents) or other
             immunosuppressive medications within 14 days of study drug administration. Inhaled or
             topical steroids, and adrenal replacement doses > 10 mg daily prednisone equivalents
             are permitted in the absence of active autoimmune disease.

          6. Participants with active, known or suspected autoimmune disease including those who
             have required systemic anti-rheumatic therapies in the preceding 2 years. Participants
             with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune
             condition only requiring hormone replacement, psoriasis not requiring systemic
             treatment, or conditions not expected to recur in the absence of an external trigger
             are permitted to enroll.

          7. Impaired cardiovascular function or clinically significant cardiovascular disease
             including, but not limited to, the following:

               1. History of acute coronary syndromes (including myocardial infarction, unstable
                  angina, coronary artery bypass grafting, coronary angioplasty or stenting) < 6
                  months prior to Screening

               2. Congestive heart failure requiring treatment (New York Heart Association Grade ≥
                  2)

               3. A known LVEF < 50% as determined by MUGA or ECHO

               4. Uncontrolled hypertension defined as persistent systolic blood pressure ≥ 150
                  mmHg or diastolic blood pressure ≥ 100 mmHg despite current therapy

               5. History or presence of clinically significant cardiac arrhythmias (including
                  resting bradycardia, uncontrolled atrial fibrillation or uncontrolled paroxysmal
                  supraventricular tachycardia)

               6. Baseline QTcF interval ≥ 480 ms.

          8. Second malignancy that requires active treatment or would interfere with treatment
             efficacy evaluation. Participants with a second malignancy treated with curative
             intent are eligible.

          9. On-going or use of systemic antibiotics during the preceding 2 weeks prior to
             enrollment

         10. Known acute or chronic infection with hepatitis B or hepatitis C virus. Participants
             treated with curative anti-viral therapy are eligible.

         11. Known history of testing positive for human immunodeficiency virus (HIV) or known
             acquired immunodeficiency syndrome (AIDS) even if fully immunocompetent on ART-due to
             the unknown effects of HIV on the immune response to combined nivolumab plus
             ipilimumab or the unique toxicity spectrum of these drugs in patients with HIV.

         12. History of a thromboembolic event < 12 weeks prior to starting study treatment.
             Examples of thromboembolic events include transient ischemia attack, cerebrovascular
             accident, deep vein thrombosis or pulmonary embolism. Catheter-related venous
             thrombosis is not considered a thromboembolic event for this trial even if < 12 weeks
             prior to starting study treatment.

         13. Use of herbal supplements, medications or foods that are moderate or strong inhibitors
             or inducers of cytochrome P450 (CYP) 3A4/5 ≤ 1 week prior to the start of study
             treatment (Section 4.5.1).

         14. History or current evidence of RVO or current risk factors for RVO (e.g., uncontrolled
             glaucoma or ocular hypertension, history of hyperviscosity or hypercoagulability
             syndromes); history of retinal degenerative disease.

        Phase II Group 1 Specific Criteria

        1. For Phase II Group 1 (Brain Metastases): Patients may have an ECOG status of 0-2 and IS
        permitted to be on corticosteroids if related to disease burden and MAY have symptomatic
        brain lesions as long as radiation or surgical intervention is not deemed to be urgently
        necessary.

          1. Symptomatic intracranial metastases may be on steroids at a total daily dose of no
             higher than 4 mg of dexamethasone or equivalent that is stable or tapering for 10 days
             prior to first treatment,

          2. have no immediate need for SRT or surgery (within 3 week prior to first treatment),

          3. have had no experience of seizure within 10 days prior to first treatment.
      
Maximum Eligible Age:N/A
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:Recommended phase II dose (RP2D) of encorafenib + nivolumab + ipilimumab
Time Frame:Up to 12 months
Safety Issue:
Description:Determination of recommended phase II dose (RP2D) of triple therapy with encorafenib + nivolumab + ipilimumab via the frequency of DLTs that are classified as either possibly, probably, or definitely related to study treatment according to NCI Common Terminology Criteria for Adverse Events (CTCAE v5.0). Adverse events and DLTs will be compiled for this triple therapy, separately. Patients receiving at least one dose any drug will be evaluable for toxicity.

Secondary Outcome Measures

Measure:Response Rate per RECIST v1.1 criteria
Time Frame:Up to 36 months
Safety Issue:
Description:Complete response [CR] + partial response [PR], per RECIST v1.1 criteria . Per RECIST v1.1, CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. For non-target lesions: Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (<10mm short axis); PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Measure:Central Nervous System (CNS) Clinical Benefit Rate (CBR)
Time Frame:Up to 36 months
Safety Issue:
Description:Clinical Benefit Rate (CBR) (in patients with brain metastasis) is defined as Complete response [CR] + partial response [PR] + stable disease [SD] >6 months) per RANO-BM criteria. Per RANO, CR: No lesion present; PR: ≥30% decrease in sum LD relative to baseline; SD: <30% decrease relative to baseline, but <20% increase in sum LD relative to nadir.
Measure:Adverse Events at least probably related to treatment
Time Frame:Up to 36 months
Safety Issue:
Description:Adverse events that are possibly, probably or definitely related to study treatment per the Criteria for Adverse Events version 5 (CTCAEv5).
Measure:Progression-free survival (PFS)
Time Frame:Up to 36 months
Safety Issue:
Description:The length of time during and after study treatment that a patient lives with cancer but it does not get worse. PFS is one way to assess how the treatment works. Per RECIST v1.1, progressive disease is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. For non-target lesions, PD: Unequivocal progression of existing non-target lesions. The appearance of one or more new lesions is also considered progression.

Details

Phase:Phase 1/Phase 2
Primary Purpose:Interventional
Overall Status:Not yet recruiting
Lead Sponsor:Jason J. Luke, MD

Trial Keywords

  • BRAFV600E/K mutation
  • metastatic melanoma

Last Updated

December 7, 2020